Central Nervous System News and Research

RSS

Study: HUCBs boost survival and maturation of hippocampal neurons

Laboratory culture studies examining the activity of human umbilical cord blood cells on experimental models of central nervous system aging, injury and disease, have shown that HUCBs provide a 'trophic effect' that enhances survival and maturation of hippocampal neurons harvested from both young and old laboratory animals.

15 Dec 2010

ONC enters exclusive long term strategic agreement with Wilmar

Ocean Nutrition Canada Limited (ONC), the world's largest Omega-3 EPA/DHA solutions provider, and supplier of MEG-3® brand Omega-3 EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) ingredients, is pleased to announce that it has entered into an exclusive long term strategic agreement with Wilmar International Limited (Wilmar), based in Singapore.

14 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

New 5-minute Memory Orientation Screening Test to identify elderly patients with dementia

A new 5-minute test to identify elderly patients with dementia promises to give doctors a more sensitive tool to use in the Annual Wellness Examination. The Memory Orientation Screening Test (MOST™) developed by Mitchell Clionsky, Ph.D., a neuropsychologist, and Emilymarie Clionsky, MD, an internist/psychiatrist, is based on their clinical experience with thousands of patients who suffer from Alzheimer's Disease and other dementias, which now afflicts more than 5 million Americans.

10 Dec 2010

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.

9 Dec 2010

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 alcohol dependent patients.

9 Dec 2010

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system disorders, announced that Cipher Pharmaceuticals is using MedAvante Centralized Ratings in their pivotal Phase 3 dermatology study.

8 Dec 2010

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Investigators at Southern Methodist University and The University of Texas at Dallas have discovered a family of small molecules that shows promise in protecting brain cells against nerve-degenerative diseases such as Parkinson's, Alzheimer's and Huntington's, which afflict millions.

8 Dec 2010

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

7 Dec 2010

Global phase III study to provide novel extended release of topiramate

Data presented yesterday showed that USL255, a novel extended-release (ER) formulation of topiramate, was associated with less fluctuation in topiramate plasma levels than immediate-release (IR) topiramate in healthy volunteers.

7 Dec 2010

Rexahn Pharmaceuticals announces US patent for cognition enhancement

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,842,683 entitled, "Neurotherapeutic Compositions and Methods."

7 Dec 2010

Study: Research findings may help identify drugs to encourage myelin repair in MS patients

Damage caused by multiple sclerosis could be reversed by activating stem cells that can repair injury in the central nervous system, a study has shown.

6 Dec 2010

Closer to restoring vision loss due to optic nerve damage

Damage to the optic nerve, connecting the eye with the brain, is a major cause of blindness. The most common culprit is glaucoma, estimated to affect more than 4 million Americans. There is currently no way to restore the lost vision, because the optic nerve, like other nerves in the mature central nervous system (CNS), cannot regenerate. Now, scientists at Children's Hospital Boston report achieving the greatest regeneration to date in the mammalian optic nerve.

4 Dec 2010

Event reporting prevents medication errors in primary care: Study

The most frequent contributors to medication errors and adverse drug events in busy primary care practice offices are communication problems and lack of knowledge, according to a study of a prototype web-based medication error and adverse drug event reporting system.

4 Dec 2010

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Zogenix, Inc. and Desitin Pharmaceuticals GmbH today announced that the Danish Medicines Agency of Denmark has approved the Marketing Authorization Application (MAA) for SUMAVEL® DosePro™ (sumatriptan injection) Needle-Free Delivery System. Denmark is the first country in Europe to grant marketing authorization for SUMAVEL DosePro for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache.

2 Dec 2010

AMT, Amgen amend GDNF gene license agreement

Amsterdam Molecular Therapeutics Holding N.V., a leader in the development of gene-based therapies, today announced that it has amended and restated its licensing agreement with Amgen for gene therapy applications incorporating the GDNF (glial cell derived neurotrophic factor) gene, to which Amgen holds rights. Financial terms were not disclosed.

2 Dec 2010

Accelerator announces Series A Preferred Stock financing of Acylin

Accelerator Corporation, a privately held, venture capital backed biotechnology investment and development company, announced today the Series A Preferred Stock financing of Acylin Therapeutics, Inc. This is the eleventh company backed by Accelerator and its first investment in intellectual property developed by either Johns Hopkins University School of Medicine or The Wistar Institute, the co-owners of the underlying technology.

1 Dec 2010

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Aphios® Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for Developing a Novel Alzheimer's Disease Nanodrug.

30 Nov 2010

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1 clinical study of NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Nov 2010

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.

30 Nov 2010

Central Nervous System News and Research

Study: HUCBs boost survival and maturation of hippocampal neurons

ONC enters exclusive long term strategic agreement with Wilmar

Depression drug appears effective in reducing pain associated with breast cancer treatment

New 5-minute Memory Orientation Screening Test to identify elderly patients with dementia

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

Global phase III study to provide novel extended release of topiramate

Rexahn Pharmaceuticals announces US patent for cognition enhancement

Study: Research findings may help identify drugs to encourage myelin repair in MS patients

Closer to restoring vision loss due to optic nerve damage

Event reporting prevents medication errors in primary care: Study

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

AMT, Amgen amend GDNF gene license agreement

Accelerator announces Series A Preferred Stock financing of Acylin

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News